Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemiparin sodium (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Embolism and thrombosis; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ABEL

    • Most Recent Events

    • 07 Jun 2012 Additional lead trial investigator (Font A) added as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Final results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 21 Oct 2011 Final results were presented at the XIII National Congress of the Spanish Society of Medical Oncology, and also in a Laboratorios Farmaceuticos Rovi media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top